ReviewCureus2022
Neurobiology of Schizophrenia: A Comprehensive Review.
Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 123 citations in OpenAlex.
- The effects of positive psychology theory in the rehabilitation nursing of Chinese patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials.Frontiers in psychiatry · 2025Pooled it
- Real-time fMRI neurofeedback modulates auditory cortex activity and connectivity in schizophrenia patients with auditory hallucinations: A controlled study.Psychiatry research. Neuroimaging · 2025Trial
- Decline in Working Memory in Stable Schizophrenia May Be Related to Attentional Impairment: Mediating Effects of Negative Symptoms, a Cross-Sectional Study.Neuropsychiatric disease and treatment · 2024Trial
- Machine learning-based integration identifies a 10-gene predictive signature and its classification patterns in schizophrenia.European archives of psychiatry and clinical neuroscience · 2026Article
- Errors or Adaptations? A Critical Review of Predictive Processing in Psychiatry.Behavioral sciences (Basel, Switzerland) · 2026Review
- Xanomeline-Trospium Validates Muscarinic Agonism as an Effective Non-Dopaminergic Treatment for Schizophrenia.International journal of molecular sciences · 2026Review
- Review
- Anxiety disorders alter cognitive-motor integration during visuomotor adaptation and retention.Experimental brain research · 2026Article
- Article
- Association of nitric oxide and neurotrophin-3 with cognitive dysfunction in schizophrenia spectrum disorders (SSD): A cross-sectional comparative study.Indian journal of psychiatry · 2026Article
- Sex-specific associations between thyroid hormones and the severity of positive and negative symptoms in patients with schizophrenia.European archives of psychiatry and clinical neuroscience · 2026Article
- Cognitive deficits in individuals with comorbid personality disorder and schizophrenia: A scoping review.Schizophrenia research. Cognition · 2026Article
- A locus coeruleus-centric framework for novelty, salience, and gamma oscillations: implications for neurostimulation, aging, and disease.Frontiers in aging neuroscience · 2026Article
- Transformer architecture for diagnosing schizophrenia disabilities through EEG analysis.Frontiers in physiology · 2026Article
- The indirect pathway hypothesis of schizophrenia: insights from perinatal asphyxia.Frontiers in physiology · 2026Review
- Pharmacist-led Review of Drug Utilization of Antipsychotic Medications in a Tertiary Government Hospital in Cebu City, Philippines.Acta medica Philippina · 2026Article
- Theory of mind variability in schizophrenia: A neurodevelopmental perspective through neurological soft signs and premorbid adjustment.Schizophrenia research. Cognition · 2025Article
- Exploring the Immunomodulatory Role of Forkhead Box Protein 3 (FOXP3) in the Pathophysiology of Neuropsychiatric Disorders.Molecular neurobiology · 2025Review
- Oxidative Stress-Mediated Neuroinflammation in the Pathophysiology of Schizophrenia.International journal of molecular sciences · 2025Review
- Cognitive Remediation as a Tool for Enhancing Treatment Dimensions of Schizophrenic Symptomatology: A Systematic Review of Randomized Controlled Trials.Brain sciences · 2025Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a debilitating disease that presents with both positive and negative symptoms affecting cognition and emotions. Extensive studies have analyzed the different factors that contribute to the disorder. There is evidence of significant genetic etiology involving multiple genes such as dystrobrevin binding protein 1 (DTNBP1) and neuregulin 1 (NRG1). There is no clear link between neurotransmitter changes and the pathophysiology of schizophrenia; however, studies have shown that subcortical dopamine dysfunction is the key mechanism. Specific regions of gray and white matter changes are observed in patients with schizophrenia; gray matter changes being more significant after the onset of psychosis. These pathological changes may be implicated in the impairment of executive functioning, attention, and working memory. The disease can be managed with pharmacological treatments based on individual patient profile, patient compliance, and disease severity. The challenge of disease management sometimes persists due to the side effects. A better understanding of the pathological processes in schizophrenia may lead to more specific and effective therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.